| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,625,000 |
| Market
Cap: |
175.17(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.59 - $5.45 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY™ (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
223,100 |
223,100 |
223,100 |
| Total Sell Value |
$0 |
$449,770 |
$449,770 |
$449,770 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Troendle August J. |
Director |
– • – |
2015-06-15 |
4 |
S |
$26.62 |
$3,034,914 |
I/I |
(113,982) |
1,892,492 |
|
- |
|
| Troendle August J. |
Director |
– • – |
2015-06-12 |
4 |
S |
$26.72 |
$3,635,763 |
I/I |
(136,018) |
2,006,474 |
|
- |
|
| Healy James |
Director |
– • – |
2015-03-18 |
4 |
A |
$0.00 |
$0 |
I/I |
239,364 |
2,893,221 |
|
- |
|
| Healy James |
Director |
– • – |
2015-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
33 |
92 |
|
- |
|
| Lanfear Dennis M |
President & CEO |
• • – |
2015-03-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,219 |
86,965 |
|
- |
|
| Lanfear Dennis M |
President & CEO |
• • – |
2015-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,084 |
71,635 |
|
- |
|
| Healy James |
Director |
– • – |
2015-03-10 |
4 |
A |
$0.00 |
$0 |
I/I |
96,098 |
2,653,857 |
|
- |
|
| Healy James |
Director |
– • – |
2015-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12 |
59 |
|
- |
|
| Lanfear Dennis M |
President & CEO |
• • – |
2015-03-10 |
4 |
A |
$0.00 |
$0 |
I/I |
803 |
86,952 |
|
- |
|
| Lanfear Dennis M |
President & CEO |
• • – |
2015-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
828 |
69,551 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2014-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
114,639 |
709,482 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2014-12-23 |
4 |
D |
$0.00 |
$0 |
I/I |
(221,538) |
0 |
|
- |
|
| Lanfear Dennis M |
See Remarks |
• • – |
2014-12-23 |
4 |
GD |
$0.00 |
$0 |
I/I |
20,000 |
1,341,921 |
|
- |
|
| Roberts George R |
10% Owner |
– – • |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
I/I |
2,499,499 |
2,499,499 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
I/I |
869,964 |
53,583 |
|
- |
|
| Healy James |
Director |
– • – |
2014-11-12 |
4 |
B |
$13.50 |
$5,750,001 |
I/I |
425,926 |
2,557,759 |
2.1 |
- |
|
| Healy James |
Director |
– • – |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,996,860 |
2,131,833 |
|
- |
|
| Healy James |
Director |
– • – |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
47 |
47 |
|
- |
|
| Lanfear Dennis M |
See Remarks |
• • – |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
I/I |
90,141 |
86,948 |
|
- |
|
| Lanfear Dennis M |
See Remarks |
• • – |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
17,734 |
68,723 |
|
- |
|
| Richards Christos |
Director |
– • – |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
55,287 |
78,836 |
|
- |
|
| Richards Christos |
Director |
– • – |
2014-11-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,956) |
23,549 |
|
- |
|
| Richards Christos |
Director |
– • – |
2014-11-12 |
4 |
OE |
$1.67 |
$44,184 |
D/D |
26,505 |
26,505 |
|
- |
|
| Daiichi Sankyo Company, Ltd |
Former 10% Owner |
– – – |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,867,426 |
2,867,426 |
|
- |
|
| Herman Alan C. |
Chief Scientific Officer |
• – – |
2014-11-12 |
4 |
A |
$0.00 |
$0 |
I/I |
45,215 |
300,164 |
|
- |
|
312 Records found
|
|
Page 12 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (2.3%) 
